SCLERO.ORG is retiring 4-24-2021. Thank you for the memories! You'll still find us in the Wayback Machine, and we'll carry your stories in our hearts forever.

Negative Results: Relaxin ® Clinical Trials for Scleroderma

Phase III Relaxin Trial Did Not Reach Primary Endpoint.
Relaxin is of no value for the treatment of scleroderma.
Author: Shelley Ensz. Scleroderma is highly variable. See Types of Scleroderma. Read Disclaimer

"Scleroderma has again proven to be an extremely difficult disease for which to develop a therapeutic treatment." Connetics 10-8-00.

Related Links

Scleroderma Research Registries. ISN.

Scleroderma Treatments & Clinical Trials. ISN.

Ineffective or Unproven Treatments for Scleroderma. ISN.

Go to Scleroderma Clinical Trials: Positive Results

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.